Study of the Effects of Dopaminergic Medications on Dopamine Transporter Imaging in Parkinson's Disease
Status:
Completed
Trial end date:
2007-05-01
Target enrollment:
Participant gender:
Summary
Study participants who have been clinically diagnosed with Parkinson disease will receive no
treatment, treatment with either levodopa, or treatment with Mirapex for a period of 12
weeks. Over the course of the study subjects will travel to the Institute for
Neurodegenerative Disorders (IND) in New Haven, Connecticut for brain imaging.
Phase:
Phase 2
Details
Lead Sponsor:
Institute for Neurodegenerative Disorders
Collaborators:
Boehringer Ingelheim United States Department of Defense